摘要
1例48岁男性患者因肝癌复发皮下注射重组人干扰素α2b,初始剂量为100万U,3次/周,1个月后调整为200万U,3次/周。初始用药1个月后患者出现畏寒、乏力、腰部及双下肢肌肉酸痛,且症状持续加重。甲状腺功能检测:促甲状腺激素(TSH)0.085 mU/L,游离三碘甲状腺原氨酸(FT3)2.20 pmol/L,游离甲状腺素(FT4)3.52 pmol/L。甲状腺超声示双侧甲状腺缩小,双侧甲状腺实质弥漫性损伤。停用重组人干扰素α2b注射液,给予左甲状腺素钠25μg/d口服。1个月后复查甲状腺功能:TSH 0.053 mU/L,FT3 2.52 pmol/L,FT4 9.51 pmol/L。
A 48-year-old man developed liver cancer recurrence and received SC recombinant human interferon ot2b. An initial dose was 1 million units thrice weekly for one month, and the dose was then increased to 2 million units thrice weekly. After 1 month of treatment, the patient developed cold intolerance, fatigue, muscle ache and pain in his loins and lower limbs, and his condition deteriorated. Thyroid function tests revealed the following levels： TSH 0. 085 mU/L, FT3 2.20 pmol/L, FT4 3.52 pmol/L. Thyroid ultrasound showed bilateral reduced thyroid size, diffuse bilateral thyroid damage. Recombinant human interferon a2b was stopped and he was given levothroxine sodium 25 ug once daily. One month later, repeat thyroid function tests showed the following levels： TSH 0. 053 mU/L, FT3 2.52 pmol/L, FT4 9.51 pmol/L.
出处
《药物不良反应杂志》
2011年第5期322-323,共2页
Adverse Drug Reactions Journal
